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Objectives: Activation of the alveolar macrophage is critical to the development of
nonischemic inflammatory lung injury. The present studies were undertaken to
determine whether the alveolar macrophage plays a similarly important role in lung
ischemia-reperfusion injury.
Methods: The left lungs of male rats were rendered ischemic for 90 minutes and
reperfused for up to 4 hours. Treated animals received liposome-encapsulated
clodronate, which depletes alveolar macrophages. Injury was quantitated in terms of
vascular permeability, tissue neutrophil accumulation, and bronchoalveolar lavage
fluid leukocyte, chemokine, and cytokine content. Lung homogenates were also
analyzed for nuclear translocation of the transcription factors nuclear factor B and
activator of protein 1.
Results: Depletion of alveolar macrophages reduced lung vascular permeability by
53% compared with that seen in control animals (permeability indices: 0.88  0.07
to 0.46  0.04, P  .001). The protective effects of alveolar macrophage depletion
correlated with a 50% reduction in tissue myeloperoxidase content (0.62 0.07 to 0.33
 0.03, P  .006) and marked reductions in bronchoalveolar lavage fluid leukocyte
accumulation. Alveolar macrophage–depleted animals also demonstrated marked re-
ductions of the elaboration of multiple proinflammatory chemokines and cytokines in
the lavage effluent and nuclear transcription factors in lung homogenates.
Conclusion: It is likely that the alveolar macrophage is the key early source of
multiple proinflammatory mediators that orchestrate lung ischemia-reperfusion in-
jury. Depleting alveolar macrophages is protective against injury, supporting its
central role in oxidant stress–induced cytokine and chemokine release and the
subsequent development of lung injury.
Lung ischemia-reperfusion injury (LIRI) occurs in up to 25% ofhuman lung transplant recipients1 and in 15% to 20% of patientsundergoing pulmonary thromboendarterectomy.2 Despite improve-ments in preservation techniques and limitation of ischemic times,reperfusion injury remains problematic after lung transplantation andmight increase the occurrence of acute and chronic rejection.
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Reperfusion injury manifests itself clinically as deterio-
rating respiratory function coupled with interstitial edema,
resulting from an increase in endothelial permeability. In
animal models this vascular injury has been defined as
biphasic.3 Although the late phase is dependent on neutro-
phil sequestration,4 the early stage is neutrophil independent
and occurs within 15 minutes of reperfusion. It has been
proposed that this early injury incites the processes that
ultimately lead to fully developed lung injury several hours
later. Because this early injury occurs well before any
significant neutrophil sequestration, it is most likely depen-
dent on the activation of a resident cell. The alveolar mac-
rophage (AM) is such a resident cell and is centrally in-
volved in a variety of lung injury models.5-10 The AM, in
response to oxidant stress in vitro, secretes a number of
chemokines and cytokines known to promote neutrophil
accumulation and therefore regulates the late phase of inju-
ry.11,12 Therefore, presuming that the early vascular injury
is dependent on a resident cell and knowing that AMs are
critical in a variety of injury models and secrete proinflam-
matory mediators in response to hypoxia and reoxygen-
ation, we hypothesized that AM depletion would be protec-
tive against LIRI. Selective depletion of AMs by means of
apoptosis13 was achieved by using the established technique
of intratracheal instillation of liposome-encapsulated clod-
ronate.5,9,10,14
Materials and Methods
Reagents
Liposomal preparations of clodronate were prepared as described
previously.13 Clodronate was a gift from Roche Diagnostics
(Mannheim, Germany). All other reagents were purchased from
Sigma Chemical (St Louis, Mo) unless otherwise specified.
Animal Model
Pathogen-free, adult male Long-Evans rats (Simonsen Labs, Gil-
roy, Calif) weighing 280 to 320 g were used for all experiments.
The University of Washington Animal Care Committee approved
all experimental protocols. Animals were anesthetized with 30 to
35 mg of intraperitoneal pentobarbital, shaved, and prepped. A
14-gauge angiocatheter was inserted into the trachea through a
midline neck incision and secured with a 4-0 braided suture.
Animals were then placed on a Harvard Rodent Ventilator (Har-
vard Apparatus Inc, Holliston, Mass) with an inspired oxygen
content of 60%, a respiratory rate of 90 breaths/min, and 2 cm H2O
of positive end-expiratory pressure. Maximal peak pressures were
maintained at less than 10 cm H2O during the operation. All
animals received 0.2 mg of atropine intramuscularly, and anesthe-
sia was maintained with inhaled halothane. Dissection was con-
ducted by using an operating microscope, and a warming blanket
was placed underneath the animals throughout the experiment. A
left anterolateral thoracotomy in the fifth intercostal space was
performed. The left lung was mobilized atraumatically, and the
inferior pulmonary ligament was divided. At this juncture, animals
received 50 units of intravenous heparin in saline solution (total
volume, 500 L). Five minutes after heparin was administered, the
left pulmonary artery, veins, and main-stem bronchus were oc-
cluded with a noncrushing microvascular clamp. During the ex-
periment, the lungs were kept moist with periodic topical applica-
tion of warm normal saline solution, and the incision was covered
to minimize evaporative losses. At the end of the ischemic period,
which was held constant at 90 minutes, the clamp was removed
from the hilum, and the lung was allowed to ventilate and reper-
fuse for periods of up to 4 hours. Animals received 0.5 mL of
warm subcutaneous saline solution per hour to maintain hydration
during the experiment. A midline incision from the neck to the
pubis was made at the end of the reperfusion period to afford
access to the chest and abdomen. Blood samples were obtained
from the inferior vena cava just before death. The heart-lung block
was rapidly excised, and the pulmonary circulation was flushed
through the main pulmonary artery with 20 mL of normal saline
solution. The lungs were separated from the heart and mediastinal
tissues and then analyzed as outlined below.
Treated animals, during a combination of ketamine- and xyla-
zine-induced anesthesia, received 100 L of liposome-encapsu-
lated clodronate in a total volume of 300 L of phosphate-buffered
saline (PBS) solution by means of direct intratracheal instillation
24 hours before the beginning of the experiment. Control animals
received the same volume of liposomes but containing saline
solution rather than clodronate. Macrophage depletion was docu-
mented by means of bronchoalveolar lavage (BAL) of lung blocks
with 6 mL of warm normal saline solution containing 0.5 mmol/L
ethylenediamine tetraacetic acid (EDTA) followed by cell counts.
In uninjured lungs the predominant cell type is the AM (99%).
The AM cell count was reduced by 74% at 24 hours after treat-
ment, and of the remaining AMs, only 10% (2.3%) remained
viable by means of trypan blue exclusion (P  .04).
Lung Permeability Index
As one quantification of lung injury caused by ischemia and
reperfusion, a lung permeability index was determined in the
following manner. Iodine 125–radiolabeled bovine serum albumin
(125I-BSA) was obtained from NEN Life Sciences (Boston, Mass).
Before use of the 125I-BSA in vivo, serial dilutions were performed
to obtain an activity of 800,000 cpm per dose. This volume of
125I-BSA, approximately 2 L of the stock solution, was then
brought to a final volume of 500 L in a 1% BSA-PBS solution.
Five minutes before removal of the hilar clamp or at an equivalent
time in control animals, the 125I-BSA preparation was injected
intravenously. Immediately before the animals were killed, 1 mL
of blood was drawn from the inferior vena cava. The heart-lung
block was then excised and flushed as described previously. The
radioactivity was quantitated in both the left and right lung, as well
as in the inferior vena caval blood sample, by using a gamma
counter. The permeability index was expressed as the ratio of
counts per minute in the left lung to counts per minute in 1.0 mL
of inferior vena caval blood, as shown in the following equation:
Permeability index
Left lung (cpm)
1.0 mL of blood (cpm)
This ratio corrects for any variation in systemic blood levels of
radioactivity and provides a reproducible measure of lung micro-
vascular permeability.15-18
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Myeloperoxidase Assay
Tissue myeloperoxidase (MPO) content was used to quantitate
neutrophil accumulation in the rat lungs. After flushing the pul-
monary circulation with 20 mL of saline solution, the lungs were
homogenized for 60 seconds in a solution of 0.5% hexadecyltri-
methylammonium bromide and 5 mmol/L EDTA in 50 mmol/L
potassium phosphate buffer (pH 6.0). Samples were then sonicated
for 40 seconds in four 10-second bursts. The homogenate was
maintained on ice between all tissue processing. Samples were
then centrifuged at 2300g for 30 minutes at 4°C, and the super-
natants were recovered. The assay buffer was composed of
0.0005% H2O2 and 0.167 mol/L o-dianisidine dihydrochloride in
100 mmol/L potassium phosphate buffer (pH 6.0). Fifty milliliters
of each sample was mixed with 1.45 mL of assay buffer, and the
change in absorbance at 460 nm over 1 minute was recorded.
Bronchoalveolar Lavage
The same groups of animals underwent BAL at the time of death.
Through an extended median sternotomy, a 14-gauge angiocath-
eter was placed in the trachea, and the lungs were lavaged indi-
vidually with 3.0 mL of warm sterile saline solution. Individual
lung BAL analysis was accomplished by clamping the contralat-
eral hilum with a noncrushing microvascular clamp. At least 80%
of the instilled fluid was recovered from each lung. This fluid was
centrifuged (1500g for 8 minutes at 4°C) to pellet the cells. The
supernatant was snap-frozen in liquid nitrogen for subsequent
cytokine and chemokine analysis after the addition of a protease
cocktail inhibitor consisting of leupeptin (1 g/mL), aprotinin (1
g/mL), trypsin inhibitor (5 g/mL), and pepstatin A (1 g/mL).
The red blood cells were lysed, and the pellet was resuspended in
normal saline solution. Cells were then counted using a hemacy-
tometer (Hausser Scientific, Reading, Pa).
Enzyme-linked Immunoassay of BAL Fluid for
Cytokine and Chemokine Content
Sandwich enzyme-linked immunoassays (ELISAs) for macro-
phage inflammatory protein (MIP) 2, cytokine-induced neutrophil
chemoattractant (CINC), MIP-1, monocyte chemotactic protein
1, and regulated on activation normal T cell expressed and secreted
were performed by adding 50 L of a 10 g/mL protein A–puri-
fied specific anti-chemokine antibody (Peprotech, Rocky Hills, NJ)
to a carbonate-coating buffer solution (pH 9.6) in a 96-well
(Dynex) immunoassay plate. The plate was incubated overnight at
4°C and subsequently washed with PBS containing 0.05% Tween.
Nonspecific binding sites were blocked with 1% BSA in saline
solution (30-minute incubation at 37°C). Samples and standards
were diluted in saline solution, and 50 L was added to each well
(1-hour incubation at 37°C). A secondary affinity-purified biotin-
ylated antibody (Peprotech) specific to the epitope being studied
(0.5-2 g/mL) was added to each well (1-hour incubation at 37°C).
After a 30-minute incubation with a streptavidin–horseradish per-
oxidase conjugate (Pierce, Rockford, Ill), the assay was developed
by adding o-phenylenediamine dihydrochloride substrate. The re-
action was stopped by adding 50 L of 3 mol/L H2SO4. The tumor
necrosis factor (TNF)  ELISA was performed according to the
manufacturer’s guidelines (R&D Systems, Abingdon, Oxon,
United Kingdom). Samples and standards were run in triplicate,
and well-to-well variation did not exceed 5%.
Electrophoretic Mobility Shift Assay
At the end of the experimental protocols, the left lungs were
snap-frozen in liquid nitrogen after flushing the pulmonary circu-
lation with 20 mL of saline solution. The frozen tissue was ground
to a fine powder and suspended in 4 mL of buffer containing
0.06% Nonidet P-40, 150 mmol/L NaCl, 10 mmol/L N-2-hydroxy-
ethylpiperazine-N-2-ethanesulfonic acid (HEPES), 1 mmol/L
EDTA, and 0.5 mmol/L phenylmethylsulfonyl fluoride. The solu-
tion was homogenized and centrifuged for 15 seconds (12,000g).
The pellet was discarded, and the supernatant was centrifuged
again for 15 seconds (12,000g). The resultant pellet was suspended
in 40 L of buffer containing 40 mmol/L NaCl, 20 mmol/L
HEPES, 0.2 mmol/L EDTA, 1.2 mmol/L MgCl2, 0.5 mmol/L
phenylmethylsulfonyl fluoride, 0.5 mmol/L dichlorodiphenyltri-
chloroethane, 25% glycerol, 5 g/mL aprotinin, and 5 g/mL
leupeptin at 4°C for 20 minutes. This solution was centrifuged for
5 minutes, the pellet was discarded, and the supernatant containing
the nuclear protein was stored at 70°C. Quantification of nuclear
protein was performed by using the bicinchoninic acid assay.
Nuclear protein (10 g) was incubated in a binding reaction
with double-stranded phosphorous 32 end-labeled oligonucleotide
containing either the nuclear factor (NF) B or activator protein
(AP) 1 binding consensus sequence (Promega, Madison, Wis).
Running unlabeled oligonucleotide probe in a cold competition
binding reaction assessed the specificity of each probe. The bind-
ing reaction was carried out at room temperature for 60 minutes,
and the proteins were resolved on a 6% nondenaturing polyacryl-
amide gel at 100 V for 1 to 2 hours. The gels were dried and
autoradiographed. Duplicate samples for each specimen were an-
alyzed.
Statistical Analysis
All groups contained 4 animals unless otherwise specified, and all
data are presented as the mean  SEM. Comparisons between
multiple groups were performed by using analysis of variance, and
those between individual groups were done by using the Bonfer-
roni modification of the t test.
Results
Changes in Lung Vascular Permeability
Five different groups of animals were studied. The first
group served as negative control animals and did not un-
dergo any intratracheal instillation or surgical manipulation.
A second group received intratracheal saline liposomes but
no surgical manipulation. A third group, the positive control
animals, underwent thoracotomy and occlusion of the left
hilum for 90 minutes, followed by 4 hours of reperfusion
(IR protocol). Additionally, both the fourth and fifth groups
were subjected to the IR protocol. The fourth group received
saline liposomes, and the fifth received liposomes contain-
ing clodronate (macrophage depleted) 24 hours before the
operation. The permeability index in animals with unma-
nipulated lungs receiving saline liposomes (0.23  0.01)
was more than double that seen in unmanipulated lungs
from animals receiving no intratracheal instillations (0.09
0.006, P  .001). A marked increase in permeability was
Cardiothoracic Transplantation Naidu et al
202 The Journal of Thoracic and Cardiovascular Surgery ● July 2003
TX
seen in IR protocol animals (0.82  0.02, P  .001)
compared with that seen in the unmanipulated groups. IR
protocol animals that received saline liposomes had a mean
permeability index of 0.88  0.07, which was not signifi-
cantly higher than that of the positive control animals. In
contrast, macrophage-depleted IR protocol animals demon-
strated a 53% (0.46 0.09, P .001) reduction in vascular
permeability compared with that seen in positive control
animals (Figure 1).
MPO Activity
MPO activity was measured in lungs from negative control
animals and animals that received saline liposomes. The
changes in absorbance at 460 nm over 1 minute in negative
control animals and saline liposome–treated animals were
0.04  0.01 and 0.07  0.03, respectively. The MPO
content from positive control animals (0.44  0.05) in-
creased significantly when compared with that from nega-
tive control animals (P .003) and was further increased in
saline liposome–treated IR protocol animals (0.62  0.07).
This finding is consistent with the demonstration of many
investigators that intratracheal liposome administration re-
sults in significant basal neutrophil accumulation in a time-
dependent fashion.14 The difference in MPO content be-
tween saline liposome–treated and positive control animals,
however, was not significant. Despite this apparent inflam-
matory side effect of liposome instillation, macrophage-
depleted IR protocol animals demonstrated a 50% (Figure
2) reduction in lung tissue neutrophil accumulation (0.33 
0.03) when compared with the saline liposome IR protocol
group (P  .02).
BAL Fluid Analysis
BAL fluid analysis was undertaken to evaluate leukocyte
content in the distal airways and alveolar compartment.
BAL leukocyte counts were recorded in the previously
described 5 groups. In negative control animals and in those
treated with saline liposomes, the cell counts were low and
not significantly different. Cell counts increased signifi-
cantly in both the positive control animals and in the saline
liposome–treated IR protocol animals compared with those
seen in their respective unmanipulated counterparts. The
predominant cell type at the end of the 4-hour reperfusion
period was the neutrophil (95%). Bronchoalveolar cell
counts were reduced in macrophage-depleted IR protocol
animals by 44% (12.8  1.3, P  .001) compared with
those seen in saline liposome–treated IR protocol animals
(Figure 3). These results are similar to the trends noted with
MPO content in macrophage-depleted animals.
Macrophage Depletion Reduces Total Lung NF-B
and AP-1 Activation After the IR protocol
To determine the mechanism of protection of macrophage
depletion in our model of LIRI, we evaluated the nuclear
translocation of 2 proinflammatory transcription factors.
There was minimal translocation of NF-B and AP-1 de-
tected in unmanipulated animals. Shown are representative
electrophoretic mobility shift assays that detail the translo-
cation of NF-B and AP-1 in IR protocol lungs with and
without macrophage depletion (Figure 4). Significant acti-
vation of NF-B and AP-1 is apparent in the animals that
underwent 90 minutes of ischemia, followed by 15 minutes
or 4 hours of reperfusion. Macrophage-depleted animals
Figure 1. Left Lung permeabilities in control and treated animals.
There is a 4-fold increase in lung vascular permeabilities in
animals receiving saline liposomes that were subjected to isch-
emia and reperfusion when compared with noninjured animals
that were administered saline liposomes (P< .001). There was no
significant difference between saline liposome–treated or un-
treated animals, whether unmanipulated or subjected to the full
IR protocol. However, in clodronate liposome–treated (macro-
phage-depleted) animals, there was a marked reduction in vas-
cular permeability (P < .025; analysis of variance: P < .001, n 
4).
Figure 2. MPO content. The increase in MPO content after isch-
emia and reperfusion was statistically significantly different from
that seen in unmanipulated lungs (P < .001). Although positive
control animals that received saline liposomes had higher tissue
MPO contents than untreated positive control animals, this dif-
ference was not significant. Tissue neutrophil accumulation was
markedly decreased in macrophage-depleted animals (P  .018;
analysis of variance: P < .001, n  4).
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appear to have markedly attenuated NF-B nuclear trans-
location at 15 minutes of reperfusion but not at 4 hours. In
contrast, AP-1 is reduced at both 15 minutes and 4 hours of
reperfusion in macrophage-depleted animals. These differ-
ences are quantitated in the densitometric analysis depicted
adjacent to the autoradiograph (Figure 4).
Macrophage Depletion Reduces the Elaboration of
Chemokines and Cytokines in BAL Fluid
The expression of selected chemokines and cytokines were
analyzed in the BAL fluid of injured lungs by using ELISAs
developed in our laboratory to demonstrate whether a re-
duction in the nuclear translocation of the aforementioned
transcription factors was associated with diminution in the
elaboration of inflammatory mediators. MIP-2, CINC, MIP-
1, and TNF- were studied because we have previously
shown that neutralizing antibodies directed against these
mediators are protective against injury (unpublished data).
Three groups were studied: unmanipulated saline liposome–
treated animals and IR protocol groups that received either
saline or clodronate liposomes. All 4 mediators studied were
significantly increased with injury (Figure 5). MIP-1,
MIP-2, and CINC increased significantly with ischemia
followed by 4 hours of reperfusion. In macrophage-depleted
animals MIP-1, MIP-2, and CINC secretion was reduced
by 70%, 64%, and 83%, respectively (MIP-1, 52 9 to 25
 3 pg/mL [P  .007]; MIP-2, 1712  308 to 751  227
[P  .04]; CINC, 109  22 to 27  11 [P  .006)). TNF-
secretion in the BAL effluent increased from 52  6 pg/mL
in unmanipulated animals to 426  43 pg/mL in the IR
protocol group (P  .05). This was also significantly re-
duced with macrophage depletion by 39% to 296  7
pg/mL (P  .05).
Discussion
Depleting AMs ameliorates lung reperfusion injury in rats,
as demonstrated by a reduction in vascular permeability and
tissue neutrophil accumulation. This reduction might repre-
sent either a delay or a genuine amelioration in injury.
Experience with this and other models of ischemia and
reperfusion would suggest that it is more likely a true
reduction. Protection is still evident despite the basal in-
crease in neutrophil sequestration that is a recognized side
effect of intratracheal liposome instillation.14 Additionally,
macrophage depletion reduces the nuclear translocation of 2
proinflammatory transcription factors, AP-1 and NF-B,
early in reperfusion. This, in turn, is associated with a
diminished expression of cytokines and chemokines, medi-
ators known to play important roles in the development of
lung injury.19 The reappearance of NF-B activation late in
reperfusion might relate to possible transcriptional activa-
tion in pulmonary artery endothelial cells20,21 or to the
stimulation of tissue neutrophils that accumulate late in
reperfusion. Nonetheless, these data strongly support a cen-
tral role for the AM in the oxidant stress–induced elabora-
tion of cytokines and chemokines in the lung.
The AM that resides at the air-tissue interface is the
early, rapid-response, immune effector cell to a wide variety
of toxic, infectious, and allergenic stimuli.22 The macro-
phage has an incredible range of biologic activities by virtue
of its ability to synthesize and secrete an array of growth
factors, cytokines, chemokines, arachidonic acid metabo-
lites, and oxygen radicals.23 Suppression of AM function
has been shown to be protective in a wide variety of models,
including lipopolysaccharide instillation, immune-complex
deposition, hyperoxia, and ozone and Pseudomonas spe-
cies–induced lung injury.5-8,10
Until recently, the role of the AM in LIRI has been
nebulous. One study using an isolated perfused lung model
showed that inhibition of macrophage function with gado-
linium improved pulmonary hemodynamics early in reper-
fusion.24 However, this effect was not associated with sig-
nificant improvement in measurable parameters of tissue
injury, such as MPO content and extravascular lung water.
Furthermore, in that study the early improvement in injury
associated with gadolinium treatment did not result in any
protective effects later in reperfusion. These data would
therefore suggest that the AM is not critical to the develop-
ment of florid lung reperfusion injury. This contradiction
might be explained in part by the model used. Although the
isolated lung model is an established and useful tool for
studying lung reperfusion injury, it unfortunately is not
physiologic. In addition to the hypotheses concerning mac-
Figure 3. BAL cell count. The BAL cell count increased signifi-
cantly in saline liposome–treated animals that underwent the IR
protocol (P < .001) and in untreated groups that underwent the IR
protocol (P < .001) when compared with that seen in their
respective nonsurgical control animals. The predominant cell
type in the unmanipulated animals was the AM, and the majority
of the cells in the reperfused lungs were neutrophils. A signifi-
cant decrease in alveolar leukocyte sequestration was clearly
demonstrated in animals that received clodronate liposomes (P<
.001; analysis of variance: P < .001, n  4).
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rophage depletion using clodronate-encapsulated liposomes
that are addressed in this study, we have also recently
demonstrated marked protection against LIRI with gadolin-
ium in our warm ischemia model (unpublished data). Mac-
rophage depletion with liposomes is an effective tool be-
cause liposomes are avidly engulfed on contact with the
Figure 4. Electrophoretic mobility shift assay (EMSA) investigating nuclear protein expression of NF-B and AP-1
in injured left lung homogenates. Lanes were run in duplicate to verify reproducibility, and the electrophoretic
mobility shift assay is depicted in B. Lanes 1 to 4 represent animals that underwent ischemia and 15 minutes of
reperfusion. Lanes 1 and 2 are samples from positive control animals, and lanes 3 and 4 represent macrophage-
depleted animals. Lanes 5 to 8 represent animals undergoing ischemia and 4 hours of reperfusion. Lanes 5 and 6
are samples from positive control animals, whereas lanes 7 and 8 represent macrophage-depleted animals. There
is a marked reduction in nuclear translocation of NF-B and AP-1 in macrophage-depleted animals at 15 minutes
of reperfusion. Although NF-B expression was increased in both groups at 4 hours of reperfusion, AP-1
expression remained decreased in macrophage-depleted animals. This was confirmed by means of densitometric
analysis and is depicted graphically in A for NF-B and in C for AP-1.
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AM.14 The intracellular release of clodronate induces apo-
ptosis,14 with minimal effect on surrounding cells. Gado-
linium, however, has the advantage of inactivating both
alveolar and pulmonary interstitial macrophages,6,7 possibly
through apoptosis.25 Although gadolinium effectively inhib-
its total body macrophage function, it is toxic when admin-
istered systemically.26 Similarly, liposomes containing clo-
dronate are not a practical means of suppressing AMs
clinically. Intratracheal liposomes incite a modest inflam-
matory response, and the long-term effects of AM depletion
are unknown. Additionally, this strategy would only target
AMs14 and would still leave a substantial number of inter-
stitial macrophages unaffected. The preferential sparing of
interstitial macrophages might in part explain the incom-
plete protection seen in this study with liposome depletion.
Certain commonly prescribed immunosuppressive drugs
might be clinically useful inhibitors of macrophage func-
tion. We have previously shown that pretreatment with
cyclosporine A (CSA) is an effective means of reducing
reperfusion injury15 and have further demonstrated that the
AM chemokine and cytokine response to hypoxia and
reoxygenation in vitro is severely blunted by CSA.11 This
suggests that in LIRI, the AM is functionally inhibited by
CSA. Although in vitro and in vivo AMs have been shown
to suppress T-cell function,27 the fear that AM depletion or
suppression might exaggerate the rejection process has been
refuted.28
Reperfusion injury has traditionally been conceptualized
as an inflammatory response to a primary endothelial injury.
However, in animal models of LIRI, cessation of blood flow
while preserving ventilation of lungs with either air or
nitrogen prevented reperfusion injury.29 This suggests that
the endothelium might not play the central role in initiating
LIRI. The lung macrophage not only resides at the air-tissue
interface but is also in close proximity to capillaries, facil-
itating its ability to influence inflammatory responses cen-
tral to the development of oxidative lung injury. AMs are
known to secrete early proinflammatory mediators, such as
TNF- and interleukin 1 with ischemia and reperfusion,
which, in turn, primes the endothelium.18 Additionally,
AMs release oxygen- and nitrogen-centered free radicals,
promote the chemotactic attraction of neutrophils, and, ul-
timately, appear more likely to be the centrally important
effector cell in the development of LIRI.
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